The DOI matches its Crossref record.
Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections
Abstract
Dalbavancin, a novel glycopeptide with a long elimination half-life ( approximately 9-12 days), was compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In a randomized, controlled, open-label, phase 2 proof-of-concept trial, adults received 1100 mg of dalbavancin (as a single intravenous infusion), 1000 mg of dalbavancin intravenously and then 500 mg intravenously 1 week later, or a prospectively defined standard-of-care regimen. A gram-positive pathogen was isolated from samples obtained from 41 (66%) of 62 patients at baseline; Staphylococcus aureus was the most prevalent species (83% of pathogens). Clinical success rates at a follow-up visit (test of cure) were 94.1% among patients treated with 2 doses of dalbavancin, 61.5% among patients treated with 1 dose of dalbavancin, and 76.2% among patients treated with a standard-of-care regimen. All treatment regimens were well tolerated; drug-related adverse reaction rates were similar across the 3 groups. These findings suggest that a regimen of 2 doses of dalbavancin administered 1 week apart is effective in the treatment of complicated, gram-positive bacterial SSTIs and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Glycopeptide and Lipoglycopeptide Antibiotics
Kahne, D., Leimkuhler, C., Lu, W., & Walsh, C. (2005) · Chemical Reviews · doi:10.1021/cr030103a · Cited by 662
Natural Products as Platforms To Overcome Antibiotic Resistance
Rossiter, S. E., Fletcher, M. H., & Wuest, W. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00283 · Cited by 622
Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey
Deresinski, S. (2005) · Clinical Infectious Diseases · doi:10.1086/427701 · Cited by 466
Metadata
- Authors
- Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-15
- Volume
- 37
- Issue
- 10
- Pages
- 1298-1303
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2151348288
- Cited by
- 231
- References
- 0
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections. https://app.cochat.ai/papers/10.1086/379015
- The paper
- Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group. (2003). Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections. Clinical Infectious Diseases. https://doi.org/10.1086/379015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.